AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28748995
Drug: Mindfulness intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness intervention (8 weekly 45-minute sessions)
Trial: 31000508
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 2.5 mg dexamethasone
Trial: 31000508
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dexamethasone injection)
Trial: 25590358
Drug: Griffonia simplicifolia/magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griffonia simplicifolia/magnesium complex (50 and 200 mg, respectively), orally administered twice a day for 3 months
Trial: 25590358
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy for MS
Trial: 22029641
Drug: short‐acting MPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short‐acting MPH (0.5 mg/kg)
Trial: 16981274
Drug: Weiansan (WAS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weiansan (WAS) 5 g, 3 times a day
Trial: 16981274
Drug: Weifuchun (WFC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weifuchun (WFC) 4 tablets, 3 times a day
Trial: 16981274
Drug: High-dose WAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose WAS
Trial: 16981274
Drug: Low-dose WAS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose WAS
Trial: 27503640
Drug: EDP-239 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-239 (100 mg single dose)
Trial: 25436815
Drug: Daily multivitamin
RxNorm normalized name: DAILY MULTIVITAMIN TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin supplementation (B complex, C, and E)
Trial: 23108516
Drug: Amoxicillin 3
RxNorm normalized name: amoxicillin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 3 g orally
Trial: 23108516
Drug: Clindamycin 600
RxNorm normalized name: clindamycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 600 mg orally
Trial: 19850639
Drug: CTC detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC detection before chemotherapy
Trial: 19850639
Drug: CTC detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC detection after chemotherapy
Trial: 19850639
Drug: CTC detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC detection before neoadjuvant chemotherapy
Trial: 18042474
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal delivery system (BTDS)
Trial: 8557011
Drug: Rocuronium (0.12,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.12, 0.17, 0.22 or 0.27 mg kg‐1, total dose of 0.5 mg kg‐1)
Trial: 8557011
Drug: Neostigmine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine administration
Trial: 7275464
Drug: 320 kcal
RxNorm normalized name: nut.tx for PKU with iron no.41 15 gram-320 kcal/81 gram ORAL BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 kcal diet with 75 micrograms of T3 daily
Trial: 24165020
Drug: Testosterone 2%
RxNorm normalized name: TESTOSTERONE 2% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone 2% transdermal gel
Trial: 22153256
Drug: Warfarin reinitiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin reinitiation in-hospital
Trial: 22153256
Drug: Warfarin reinitiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin reinitiation in selected patients
Trial: 22153256
Drug: Factors associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors associated with restarting warfarin
Trial: 19948753
Drug: Generalized physiotherapy
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generalized physiotherapy (G; n = 27)
Trial: 16315785
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 800 microg daily for 6 months
Trial: 12455155
Drug: D-003 50
RxNorm normalized name: D-panthenol 50
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-003 50 mg
Trial: 12455155
Drug: D-003 50
RxNorm normalized name: D-panthenol 50
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-003 50 mg/day
Trial: 12455155
Drug: D-003 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-003 5, 25 and 50 mg/day
Trial: 8749687
Drug: Modeled bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modeled bicarbonate dialysis (M; 28 mmol/L rising to 35 mmol/L at 3 h, 40 mmol/L at 4 h)
Trial: 8749687
Drug: High bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High bicarbonate dialysis (H; 40 mmol/L)
Trial: 8749687
Drug: Standard bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bicarbonate dialysis (S; dialysate HCO3- 30 to 34 mmol/L)
Trial: 8749687
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (S, H, M)
Trial: 2344857
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 1.5 mg digoxin over 6 hours
Trial: 2344857
Drug: Bolus injections
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injections of 0.5 mg digoxin 8 hours apart (three injections)
Trial: 7407759
Drug: IMPY administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPY administered via single iv bolus
Trial: 7407759
Drug: IMPY administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPY administered via intermittent 5-day bolus
Trial: 7407759
Drug: IMPY administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPY administered via 5-day continuous infusion
Trial: 30177490
Drug: Dihydroergotoxine mesylate
RxNorm normalized name: Dihydroergotoxine mesylate
DrugBank: Dihydroergotoxine (DB16602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotoxine mesylate 2.5 mg orally twice daily
Trial: 27996280
Drug: Intravenous MgSO₄
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous MgSO₄
Trial: 24219370
Drug: Carrageenan nasal
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrageenan nasal spray, applied three times daily for seven days
Trial: 24219370
Drug: Carrageenan nasal
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrageenan nasal spray
Trial: 19729979
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel 40 mg/m² (group A)
Trial: 19729979
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel 35 mg/m² with gemcitabine 600 mg/m² (group B)
Trial: 16424649
Drug: Intravenous anti-D
RxNorm normalized name: anti-D (rh) immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anti-D (50 microg/kg i.v. initially, with repeated doses every 4 weeks for 12 patients)
Trial: 16424649
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous immunoglobulin (IVIG, 250 mg/kg for 2 consecutive days)
Trial: 11006039
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m², Paclitaxel 200 mg/m², Cyclophosphamide 500 mg/m² with G-CSF 300 microg daily for 5 days, followed by Carboplatin AUC-5 and Paclitaxel 135 mg/m²
Trial: 1543675
Drug: 1% terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% terbinafine cream
Trial: 6337767
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of insulin [2.5 units h‐1 (m2 of body surface area)‐1]
Trial: 6337767
Drug: Intravenous angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous angiotensin II (20 ng min‐1 kg‐1) with insulin
Trial: 6337767
Drug: Intravenous angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous angiotensin II (20 ng min‐1 kg‐1) without insulin
Trial: 31554423
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 to 600 mg loading dose, 75 mg daily thereafter)
Trial: 26143741
Drug: 2.2 g
RxNorm normalized name: Vaporizer Safeguard 2.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 g marine n-3 polyunsaturated fatty acids (PUFA)
Trial: 22341868
Drug: Fenofibrate 200mg
RxNorm normalized name: FENOFIBRATE 200MG CAP
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200mg daily for 12 weeks
Trial: 15881488
Drug: Pioglitazone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone monotherapy and pioglitazone plus sulfonylurea
Trial: 12078335
Drug: Carbolithium Once‐A‐Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbolithium Once‐A‐Day (600 mg)
Trial: 12078335
Drug: Standard Carbolithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Carbolithium (300 mg b.i.d.)
Trial: 23456673
Drug: Tazarotene gel
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene gel (3.7 g applied once daily)
Trial: 23456673
Drug: Tazarotene foam
RxNorm normalized name: tazarotene Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene foam (3.7 g applied once daily)
Trial: 23456673
Drug: Tazarotene gel
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene gel
Trial: 23456673
Drug: Tazarotene foam
RxNorm normalized name: tazarotene Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene foam and gel
Trial: 21241910
Drug: Brimonidine-timolol fixed
RxNorm normalized name: brimonidine / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine-timolol fixed combination, 1 drop immediately after surgery
Trial: 15106795
Drug: Drug prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug prescription patterns
Trial: 15106795
Drug: Consultations and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consultations and medications
Trial: 9850899
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (oxybuprocaine 0.4% drops)
Trial: 7861719
Drug: Cyclosporin at
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin at an average dose of 3.9 mg/kg/day for up to three years
Trial: 7861719
Drug: Cyclosporin treatment
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin treatment continued for an additional two years
Trial: 2682864
Drug: Aerosol inhalation
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol inhalation of salbutamol (SAL)
Trial: 2682864
Drug: Aerosol inhalation
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol inhalation of N‐acetyl cysteine (AC)
Trial: 2682864
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with aerosol inhalation of SAL and AC followed by CPT (COMB)
Trial: 412450
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Trial: 412450
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Trial: 412450
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Trial: 17302257
Drug: Enfuvirtide (ENF)
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (ENF) 90 mg (1.0 ml)
Trial: 17302257
Drug: Enfuvirtide (ENF)
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (ENF) 45 mg (2 x 0.5 ml)
Trial: 17302257
Drug: Injection vehicle
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection [Penmenvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection vehicle (ENF buffer minus ENF)
Trial: 10875491
Drug: Topical beclomethasone
RxNorm normalized name: beclomethasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beclomethasone treatment
Trial: 1589705
Drug: Doxycycline triple
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline triple therapy (with bismuth subcitrate and metronidazole)
Trial: 1589705
Drug: Tetracycline HCl
RxNorm normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline HCl triple therapy (with bismuth subcitrate and metronidazole)
Trial: 22527813
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy (group 1)
Trial: 22527813
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy (group 2)
Trial: 18006206
Drug: Tray based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tray based whitening system (Colgate Visible White PF Mint) using a 6% hydrogen peroxide gel applied in the tray twice daily for 30 min
Trial: 14980755
Drug: Other medical
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other medical therapies (oral contraceptives and/or prostaglandin synthetase inhibitor)
Trial: 11777881
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (2-4 g intravenously)
Trial: 939070
Drug: Sotalol with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol with diuretic
Trial: 27200503
Drug: Metreleptin (0.01,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (0.01, 0.1 and 0.3 mg per kg body weight) administered once in a 1-day-long trial
Trial: 27200503
Drug: Metreleptin (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (0.08 and/or 0.12 mg kg(‐1)) administered for 16 weeks
Trial: 27200503
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 16 weeks
Trial: 23146150
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide (1 mg/d)
Trial: 16086757
Drug: Control (passive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (passive treatments)
Trial: 11850863
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide pneumococcal vaccine
Trial: 7487465
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir during ALA therapy (group 1)
Trial: 6127719
Drug: ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ipratropium bromide (160 micrograms daily)
Trial: 6127719
Drug: thiazinamium methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiazinamium methyl sulphate (900 mg daily)
Trial: 27814302
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication (dosage titrated by physician)
Trial: 17335691
Drug: Myeloid growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloid growth factors (MGFs) used at varied schedules, doses, and durations differing from FDA approved prescribing information.
Trial: 17335691
Drug: Myeloid growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloid growth factors (MGFs) administered on the same day as chemotherapy.
Trial: 16291353
Drug: Hood (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hood (1.5 mg epinephrine in 4 mL saline [3%])
Trial: 16291353
Drug: Mask (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mask (1.5 mg epinephrine in 4 mL saline [3%])
Trial: 10460118
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy interventions (physical function, social and leisure activities, other)
Trial: 10460118
Drug: Median treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median treatment time for a session
Trial: 10460118
Drug: Variability in
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variability in treatment delivery
Trial: 7528271
Drug: ICE chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE chemotherapy with G‐CSF
Trial: 2381617
Drug: 2% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% clindamycin cream
Trial: 2381617
Drug: Lower concentrations
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower concentrations of clindamycin cream (0.1% and 1%)
Trial: 23224127
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) early treatment (IVB1)
Trial: 23224127
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone (IVT) early treatment (IVT1)
Trial: 23224127
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) late treatment (IVB2)
Trial: 23224127
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone (IVT) late treatment (IVT2)
Trial: 18165205
Drug: Placebo (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (other drug than spironolactone)
Trial: 10954340
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g in 200 ml water)
Trial: 10718784
Drug: Water (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (200 ml) (control)
Trial: 9177508
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of endoscopic variceal ligation (EVL) and endoscopic sclerotherapy (EST)
Trial: 8415265
Drug: Budesonide forte
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide forte aerosol Polfa, 200 micrograms four times daily
Trial: 21087288
Drug: NETE-8 (norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETE-8 (norethisterone enanthate 200 mg every 8 weeks plus testosterone undecanoate 1000 mg)